Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2019

View Archived Issues

DKK2 unveiled as a potential therapeutic target for lung cancer

Where TH2 cells go, blood vessels are built

New metabolic syndrome target

Wild moms are good for offspring microbiome

First-in-human data presented for GSK-3036656

Recruitment ongoing in first in human trial of NOV-1601

JZP-458 to enter phase II/III development

Cleave Therapeutics obtains financing to advance its VCP/p97 inhibitor

BDGR-4 shows prophylactic and treatment potential for encephalitic alphaviruses

Cue Biopharma begins phase I study of CUE-101

Phase III data announced for setmelanotide in POMC and LEPR deficiency obesities

Phase I/II study of ASTX-295 recruiting participants

Serum visfatin as a diagnostic marker of patients with AMI

Apoptosis regulator Bcl-2 inhibitors patented by Zeno Royalties & Milestones

Changsha Hooz Bioscience & Technology compounds target UHRF1 and/or HDAC1

PI4KIII-beta inhibitors discovered at GlaxoSmithKline

Idorsia Pharmaceuticals describes C5aR antagonists

Favorable safety and PK data from phase Ib/IIa study of recombinant human plasma gelsolin

FDA grants approval to initiate phase Ib/II stud of L-DOS-47 plus doxorubicin in pancreatic cancer

Cancer Research UK and Hummingbird Bioscience to partner to advance HMBD-001

Servier enrolling subjects in first-in-human trial of S-65487

Chiesi Farmaceutici initiates phase I study of CHF-6523 in COPD

Novel T-cell subtype predicts risk of anaphylactic shock

Applied Therapeutics reports data from SAD portion of phase I/II study of AT-007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...